General information, not individual medical advice. This article cannot take account of your medical history, medicines or circumstances. Speak to a GP, pharmacist or other healthcare professional before making significant changes to what you eat or to any treatment, particularly if you have a medical condition, follow a prescribed diet, take medicines affected by food intake, are pregnant or breastfeeding, or have an eating disorder now or in the past.
Stopping Mounjaro can bring up mixed feelings: relief from side effects, concern about cost, pregnancy plans, a plateau, or worry that the weight will return. Those are reasonable reasons to ask what happens next. The available evidence suggests that weight regain is common after stopping tirzepatide, but it does not mean every person will regain the same amount or at the same speed.
What the withdrawal trial found
SURMOUNT-4 followed adults with obesity or overweight plus a related health condition. Everyone first received tirzepatide for 36 weeks, alongside diet and activity counselling. Participants who reached a maximum tolerated dose were then assigned either to continue tirzepatide or switch to placebo for another 52 weeks.
From week 36 to week 88, the mean body weight of those who switched to placebo rose by 14.0% relative to their week-36 measurement. People who continued tirzepatide lost a further 5.5% on average over the same period. The placebo group's mean weight at week 88 was still below its starting average, so "regain" does not mean everyone returned to their original weight. The SURMOUNT-4 trial report explains this withdrawal design and result.
This is a strong signal that the medicine's effect often needs ongoing treatment to be maintained. It is not a perfect model of every real-life stop: trial participants were selected, had already completed 36 weeks and tolerated a high dose, and received structured counselling.
Why weight can return
Tirzepatide reduces appetite and changes fullness signals while it is active. When treatment stops, those effects fade. Hunger may return, portions may feel less satisfying, and the body can push back against weight loss. None of that is a failure of discipline. It is one reason obesity care is better understood as long-term health treatment than as a short course with a guaranteed finish line.
If you are thinking about stopping
Talk to the prescriber before changing or ending treatment. Ask what is driving the decision, whether side effects need assessment, how blood glucose or other conditions will be monitored, and what support will continue. If you use Mounjaro for type 2 diabetes, stopping may affect glucose management and your diabetes plan may need to change. Do not stop insulin or another diabetes medicine without advice.
If treatment must stop, ask for a practical follow-on plan: regular weight and health reviews, nutrition support that remains affordable and realistic, strength and activity goals that fit your body, and clear thresholds for getting help. If cost or supply is the issue, say so; it may change what options are available.
People who are planning pregnancy should discuss timing with their clinician. MHRA guidance says to stop tirzepatide at least one month before trying to become pregnant. If pregnancy happens while taking it, contact a healthcare professional promptly.
The most useful aim is not to promise that the scales will never rise. It is to decide, with clinical support, how to protect health and respond early if appetite, weight or glucose begins to change.
Sources
Links checked on 25 September 2026.
Date Written:
12/06/2026
Role:
Clinical Pharmacist
Date Checked:
12/06/2026
Role:
Pharmacist
Wondering whether treatment is an option?
Check your BMI against the UK eligibility thresholds, or complete a free online assessment and a GPhC-registered prescriber will review whether treatment is appropriate for you.